Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma
After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition thera...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-09-01
|
| Series: | Chronic Diseases and Translational Medicine |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2095882X19300684 |
| _version_ | 1811327765548367872 |
|---|---|
| author | Wei-Bo Yu Jian-Yu Rao |
| author_facet | Wei-Bo Yu Jian-Yu Rao |
| author_sort | Wei-Bo Yu |
| collection | DOAJ |
| description | After two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings. However, the percentage of patients who benefit from anti-PD-L1/anti-PD1 therapy is still low. Many questions have been raised in the development of biomarker-driven approaches for disease classification and patient selection. In this perspective, we discuss PD-L1/PD1 expression in urothelial bladder carcinoma, review approved anti-PD-L1/anti-PD1 agents for bladder cancer treatment and current ongoing studies investigating combination treatment strategies, and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy. Keywords: Immune checkpoint therapy, Urothelial carcinoma, Bladder cancer, Programmed death-ligand 1, Programmed death-1 |
| first_indexed | 2024-04-13T15:12:45Z |
| format | Article |
| id | doaj.art-d9de201c2d614d868469c89bd5ca9cae |
| institution | Directory Open Access Journal |
| issn | 2095-882X |
| language | English |
| last_indexed | 2024-04-13T15:12:45Z |
| publishDate | 2019-09-01 |
| publisher | Wiley |
| record_format | Article |
| series | Chronic Diseases and Translational Medicine |
| spelling | doaj.art-d9de201c2d614d868469c89bd5ca9cae2022-12-22T02:41:57ZengWileyChronic Diseases and Translational Medicine2095-882X2019-09-0153170177Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinomaWei-Bo Yu0Jian-Yu Rao1Department of Pathology and Laboratory Medicine, David Geffen School of Medicine University of California at Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095, USACorresponding author.; Department of Pathology and Laboratory Medicine, David Geffen School of Medicine University of California at Los Angeles, 10833 Le Conte Ave., Los Angeles, CA 90095, USAAfter two decades of unchanged paradigms, the treatment strategies for advanced urothelial bladder cancer have been revolutionized by emerging programmed death ligand-1 (PD-L1)/programmed death-1 (PD1) inhibition therapy. Increased evidence is demonstrating the efficacy of PD-L1/PD1 inhibition therapy in both second-line and first-line settings. However, the percentage of patients who benefit from anti-PD-L1/anti-PD1 therapy is still low. Many questions have been raised in the development of biomarker-driven approaches for disease classification and patient selection. In this perspective, we discuss PD-L1/PD1 expression in urothelial bladder carcinoma, review approved anti-PD-L1/anti-PD1 agents for bladder cancer treatment and current ongoing studies investigating combination treatment strategies, and explore PD-L1 expression status for the evaluation of bladder cancer immunotherapy. Keywords: Immune checkpoint therapy, Urothelial carcinoma, Bladder cancer, Programmed death-ligand 1, Programmed death-1http://www.sciencedirect.com/science/article/pii/S2095882X19300684 |
| spellingShingle | Wei-Bo Yu Jian-Yu Rao Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma Chronic Diseases and Translational Medicine |
| title | Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma |
| title_full | Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma |
| title_fullStr | Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma |
| title_full_unstemmed | Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma |
| title_short | Programmed death ligand-1/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma |
| title_sort | programmed death ligand 1 programmed death 1 inhibition therapy and programmed death ligand 1 expression in urothelial bladder carcinoma |
| url | http://www.sciencedirect.com/science/article/pii/S2095882X19300684 |
| work_keys_str_mv | AT weiboyu programmeddeathligand1programmeddeath1inhibitiontherapyandprogrammeddeathligand1expressioninurothelialbladdercarcinoma AT jianyurao programmeddeathligand1programmeddeath1inhibitiontherapyandprogrammeddeathligand1expressioninurothelialbladdercarcinoma |